ABSTRACT
INTRODUCTION
The Congenital Disorders of Glycosylation (CDG 5 ) are a diverse group of inherited diseases that impair protein glycosylation (Freeze, H.H. 2001, Marquardt, T. and Denecke, J. 2003) (Fig. 1) . Type I disorders result from mutations in the N-linked oligosaccharide pathway and lead to unoccupied glycosylation sites on some proteins.
Twelve types of CDG (Ia-IL) in this group include defects in monosaccharide activation, glycosyltransferases, or in non-catalytic partners involved in the biosynthesis of the glucose (Glc) 3 -mannose (Man) 9 -N-acetyl glucosamine (GlcNAc) 2 -P-P-Dolichol (Dol)
lipid-linked oligosaccharide (LLO) (Jaeken, J. 2003, Marquardt, T. and Denecke, J. 2003) .
By far the most common disorder is CDG-Ia, which is caused by mutations in PMM2 encoding phosphomannomutase (PMM) (Van Schaftingen, E. and Jaeken, J.
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To define the degradation products of the compounds in the presence of human serum or fetal bovine serum (FBS), C-I and C-II were added to the sera and the reactions were followed by mass spectrometry. After 30 min in human serum, neither of the compounds could be detected. C-I showed two main degradation products with the molecular weights 545.3 (acetoxymethyl-2,3,4,6-tetra-O-acetyl--D-mannopyranosyl phosphate sodium salt) and 371.3 (2,3,4,6-tetra-O-acetyl--D-mannopyranose sodium salt), respectively (data not shown). C-II showed the two corresponding degradation products, 665.4
(acetoxymethyl-2,3,4,6-tetra-O-ethyloxycarbonyl--D-mannopyranosyl phosphate sodium salt) and 491.4 (2,3,4,6-tetra-O-ethyloxycarbonyl--D-mannopyranose sodium salt).
General characterization and toxicity
In the cell, C-I is hydrolyzed to Man-1-P + 6AcOH +2CH 2 O, and C-II generates Man-1-P + 2AcOH + 2CH 2 O + 4C 2 H 5 OH + 4CO 2 . We analyzed the effects of these potentially toxic products on cellular protein synthesis and growth. C-I does not affect cell growth (24 hr), but 100 µM C-II inhibits growth by 50% and growth is completely inhibited at 250 µM. (Fig. 3A) . Up to 250 µM, C-I had no effects on protein synthesis (not shown), but C-II decreased protein synthesis above 100 µM in control, CDG-Ia and CDG-Ib cells (Fig. 3B ). CDG-Ia fibroblasts incubated in 150 µM C-II for 25 hr showed very few Trypan Blue stained cells, whereas at 200 µM, more than 60% of the cells stained (data not shown). Since our primary goal is to determine the effects on LLO and glycoprotein synthesis, we concentrated on short-term incubations. Fig. 4A , lower chromatogram). Both compounds completely normalized LLO size, but C-II was about 2-fold more effective than C-I (Fig. 4B ). These results suggested that the Man-1-P compounds supplemented the depleted GDP-Man pools in CDG-Ia cells. To confirm this, we directly measured the pools in control and CDG-Ia fibroblasts in the presence of 0, 100 or 250 µM C-II. The GDP-Man pool is about 3.5-fold smaller in CDG-Ia cells compared to control, but addition of C-II considerably increased it in the patient cells (Table I) .
CDG-Ia cells use C-II-derived Man-1-P more efficiently than Man-1-P derived from Man.
Man (1 mM) can correct GDP-Man pools and normalize LLO profiles in CDG-Ia and CDG-Ib cells (Panneerselvam, K. and Freeze, H.H. 1996) . To determine whether Man-1-P derived from C-II is used more efficiently than Man, we measured the ability of each to (Fig. 5A-C ).
C-II corrects glycosylation of DNAse-I in CDG-Ia fibroblasts
In order to investigate the effects of Man versus C-II on the rate of N-glycosylation we employed a glycosylation assay described by Nishikawa and Mizuno (Nishikawa, A. and Mizuno, S. 2001) . In this assay, a construct of DNAse-I, having one potential glycosylation site (glycosylated to 70-80 % in control cells), is introduced via adenoviral transduction into fibroblasts. The effect of added compounds on its glycosylation can then be monitored by 35 S-amino acid metabolic labeling in the presence of compound, immunoprecipitation and separation of glycosylated and non-glycosylated species by SDS-PAGE. Phosphorimaging is used to quantify the amount of label in each species. In the CDG-Ia fibroblasts used here, we found 60 % of the label in the glycosylated version of DNAse-I ( Since these defects are usually partial, increasing GDP-Man might normalize truncated LLO structures, especially where the mutations increase the K m for GDP-Man.
We chose several types of CDG-I cells, incubated them with C-I or C-II and analyzed the LLO structures. CDG-Ie results from mutations in DPM1 (Imbach, T., Schenk, B., et al. 2000 , Kim, S., Westphal, V., et al. 2000 , the catalytic subunit for Dol-P-Man synthase (Dol-P +GDP-Man Dol-P-Man). A homozygous point mutation in DPM1 of patient CH increases the Km of GDP-Man about 6-fold yielding a truncated Man 5 GlcNAc 2 -P-P-Dol precursor (Fig. 7, upper chromatogram) , but providing either C-I (300 µM) or C-II (300 µM) corrected synthesis towards full-size LLO. Again, C-II is more efficient than C-I (Fig. 7 , middle and lower chromatograms, respectively). Another patient (MA) with an unknown defect (CDG-Ix) synthesizes primarily Man 5 GlcNAc 2 -P-P-Dol precursor (Fig   8, upper chromatogram) . 300 µM C-I partially corrects the abnormal pattern (middle chromatogram) whereas 300 µM C-II fully corrects it (lower chromatogram), suggesting that the defect may involve an enzyme that utilizes Dol-P-Man. Because C-II has greater
efficiency, further studies only tested this compound. Fibroblasts from a CDG-Ig patient (MH), who has a deficiency in ALG12, synthesizes only Man 7 GlcNAc 2 -P-P-Dol DISCUSSION Cultured fibroblasts from CDG-Ia patients have small GDP-Man pools, which can be corrected with 1 mM Man (Panneerselvam, K. and Freeze, H.H. 1996) , but Man therapy failed in patients (Marquardt, T. and Denecke, J. 2003) . As an alternative therapy for them, we synthesized two hydrophobic, membrane permeable versions of Man-1-P, using a different strategy than previously reported (Muus, U., Kranz, C., et al. 2004 , Rutschow, S., Thiem, J., et al. 2002 . Acetoxymethyl groups neutralized the negative charges on the phosphate and the hydrophobicity of the hydroxyl groups was increased by their conversion to either acetyl (C-I) or ethyl carbonate (C-II) esters. Once inside the cells, cytosolic esterases generate the parent compounds. C-I appeared to be non-toxic even at high concentrations while C-II began to inhibit protein synthesis above 100 µM. This suggested that either C-I was less permeable than C-II or that the products released from C-II on hydrolysis were more toxic than the acetate released from C-I. Since both C-I and C-II contain two acetoxymethyl esters, they are unlikely to cause the toxicity. The half life of C-I is much shorter than that of C-II, both in culture medium and human serum.
This may, at least partially account both for the higher efficiency and higher toxicity of C-II. More studies are needed to assess the basis of toxicity and to design other less toxic derivatives. The main goal of these studies was to prove that these derivatives could rescue defective glycosylation in CDG cells. competing and counteracting factors (see Fig. 1 ). For instance, Man efficiently enters the cell via facilitated diffusion transporter, but C-I and C-II do not. Once inside the cell, the great majority of Man-6-P (95-98%) derived from Man is rapidly converted to fructose-6-P by PMI, leaving only a small amount for glycosylation. The relative activities and substrate affinities of the enzymes competing for Man-6-P and Man-1-P determine whether Man or the compounds are used more efficiently. In PMM-deficient CDG-Ia cells, C-II is more efficient than Man, since the normal PMI activity catabolizes most of the Man-6-P and prevents its accumulation, while reduced PMM activity encourages entry of Man-1-P into glycosylation. In contrast, PMI-deficient CDG-Ib cells use Man more efficiently than C-II. This finding underscores the role of PMI as both a provider of Man-6-P for glycosylation and a regulator against accumulation of Man-6-P within the cell. C-II was also able to correct glycosylation of an over-expressed glycoprotein (DNAse-I) in CDG-Ia cells, whereas Man had no effect. This shows that the effects of C-II seen on LLO correction not only reflect a change in the steady-state of the LLO intermediates, but actually provides a dose-dependent increase in glycosylation.
C-II slightly increased the GDP-Man pool in control fibroblasts, suggesting that fibroblasts from other CDG-I patients with defects in LLO synthesis might benefit from An exception is Dol-P-Man synthase (CDG-Ie) where the K m for GDP-Man is 6 µM, but a homozygous point mutation in patient CH increases the K m to about 40 µM (Kim, S., Westphal, V., et al. 2000) . Increasing GDP-Man is predicted to have a positive effect and increase the amount of Dol-P-Man synthesized. By analogy, the corrected CDG-Ix patient probably has mutations that increase the K m for a GDP-Man-dependent reaction, perhaps involving the Dol-P-Man donor.
These initial experiments provide evidence that hydrophobic Man-1-P compounds may be useful as a potential therapeutic. Synthesis of other compounds with lower toxicity and greater stability must be addressed in future studies.
MATERIALS AND METHODS

Materials
Minimal Essential Medium-alpha ( -MEM) and Dulbecco's modified Eagle's medium Human serum was prepared from blood drawn just prior to the experiment from a coauthor.
Synthesis of Man-1-P derivatives
General. All solvents and reagents used were reagent grade or better and were used as 
Diacetoxymethyl 2,3,4,6-tetra-O-acetyl-D-mannopyranosyl phosphate (C-I, 5)
D-Mannose (3.0 g) in pyridine (50 mL) and acetic anhydride (25 mL) was stirred overnight at room temperature. Co-evaporation with toluene yielded 1,2,3,4,6-penta-Oacetyl-/ -D-mannopyranose as a syrup (1, 7.1 g), which was dissolved in CH 2 Cl 2 (10 mL), and HBr in acetic acid (30 %, 30 mL) was added. The mixture was stirred at room temperature and its progress was monitored by TLC (silica gel, toluene-EtOAc 6:4).
After 2 h, the reaction was poured into ice-water/CH 2 Cl 2 mixture, and the organic layer was washed with ice-cold saturated aqueous sodium bicarbonate, water, dried (magnesium sulfate), and evaporated. The residual crude 2,3,4,6-tetra-O-acetyl--D-mannopyranosyl bromide (2, 6.5 g) was stored at 4 ˚C. This material (1.6 g) was dissolved in CH 2 Cl 2 (12 mL) containing dibenzyl phosphate (1.6 g) and freshly activated powdered molecular sieves (4Å, 4 g), and was stirred at room temperature for 30 min, after which silver carbonate (4.0 g) was added. Progress of the reaction was monitored by TLC (toluene-EtOAc 6:4). A slower, UV-absorbing spot appeared, with the disappearance of the bromo-sugar. After 1 h, the mixture was filtered through Celite, washed with aqueous sodium thiosulfate, water, dried (magnesium sulfate) and evaporated. The residue was purified by chromatography on silica gel (toluene-EtOAc, 6:4), and fractions containing the main compound were combined and evaporated. The residue (1.40 g) showed a strong peak at m/z 631.1 (M+Na) in the positive ion ESI-MS spectrum, as expected for dibenzyl 2,3,4,6-tetra-O-acetyl--D-mannopyranosyl phosphate (3). This material (600 mg) was taken up in EtOAc (18 mL) and added to a slurry of Pd/C (200 mg) in EtOAc (2 mL). The mixture was stirred under an atmosphere of hydrogen at room temperature until the TLC (EtOAc-acetic acid-methanol-water, 12:3:3:2) showed complete debenzylation of the phosphate moiety. The mixture was filtered through Celite, and the filtrate was evaporated and co-evaporated with dry acetonitrile. The residue, containing crude 2,3,4,6-tetra-O-acetyl -D-mannopyranosyl phosphate (4), was taken up in dry acetonitrile (10 mL), and stirred at room temperature while adding acetoxymethyl bromide (1.6 mL) and diisopropylethylamine (1.6 mL, 9.6 mmol). Stirring was continued overnight while TLC analysis showed a major new, fastmigrating spot (R f 0.95 in EtOAc-acetic acid-methanol-water, 12:3:3:2; R f 0.3 in toluene- 
Diacetoxymethyl 2,3,4,6-tetra-O-ethyloxycarbonyl-D-mannopyranosyl phosphate (C-II, 10)
D-Mannose (3 g, 16.67 mmol) in pyridine (50 mL) was cooled in an ice bath and ethyl chloroformate (15.8 mL) was added dropwise, and the reaction was stirred overnight at room temperature. TLC (toluene-EtOAc 8:2) showed the formation of a major spot (R f 0.5). Water (2 mL) was added to the mixture, and after 15 min the mixture was partitioned between EtOAc and water. The organic phase was washed with water, aqueous sulfuric acid (1 M), aqueous saturated sodium bicarbonate, dried (magnesium sulfate) and evaporated. The resulting orange-colored syrupy residue (8.9 g) was an anomeric mixture of 1,2,3,4,6-penta-O-ethyloxycarbonyl-D-mannopyranoses (6). This material (2.0 g) was dissolved in CH 2 Cl 2 (2 mL) and HBr in acetic acid (30 %, 8 mL) was added. The mixture was stirred at room temperature until TLC (toluene-EtOAc 8:2)
showed accumulation of a product with a slightly higher R f value (~ 4h). The mixture was partitioned between ice-water and CH 2 Cl 2 , the organic layer was washed with ice-cold aqueous saturated sodium bicarbonate, water, dried (magnesium sulfate), and evaporated. This material, 2,3,4,6-tetra-O-ethyloxycarbonyl--D-mannopyranosyl bromide (7, 1.16 g) was dissolved in dry CH 2 Cl 2 (12 mL), and dibenzyl phosphate (1.0 g) and activated powdered molecular sieves (4Å, 2.0 g) were added and the mixture stirred for 30 min, after which silver carbonate (2 g) was added. The mixture was stirred at room temperature overnight, and the reaction was monitored by TLC (toluene-EtOAc 6:4). A major slower, UV-absorbing spot developed, as the bromo-sugar disappeared.
The mixture was filtered through Celite, washed with aqueous sodium thiosulfate, water, dried (magnesium sulfate), and evaporated. To assure that the UV absorbing material only consisted of the compound assayed, all peaks were characterized by mass spectrometry.
Cells
Control human dermal fibroblasts were obtained from ATCC (Rockville, MD). CDG patient cells were obtained by informed consent from physicians treating the patients.
Cells were grown in -MEM with 5 mM glucose, 2 mM L-glutamine and 10 % FBS at 37˚C in a 5 % CO 2 atmosphere.
Growth inhibition and Trypan Blue exclusion
To assess the cytotoxicity of C-I and C-II, control fibroblasts were plated in 6 well plates (M 7 ) and Glc 3 Man 9 GlcNAc 2 (G 3 M 9 )) are indicated. 
